

Regular Meeting of the Santa Clara County Health Authority d.b.a. Santa Clara Family Health Plan OPEN SESSION - Pharmacy & Therapeutics Committee Thursday, June 21, 2018 6:00 PM - 8:00 PM

210 E. Hacienda Avenue Campbell, CA 95008

MINUTES

Voting Committee Members	Specialty	Present (Y or N)
Jimmy Lin, MD	Internal Medicine	Υ
Hao Bui, BS, PharmD	Community Pharmacy (Walgreens)	N
Minh Thai, MD	Family Practice	N
Amara Balakrishnan, MD	Pediatrics	N
Peter Nguyen, MD	Family Practice	Y
Jesse Parashar-Rokicki, MD	Family Practice	Υ
Narinder Singh, PharmD	Health System Pharmacy (SCVMC)	Υ
Ali Alkoraishi, MD	Adult & Child Psychiatry	Υ
Dolly Goel, MD	VHP Chief Medical Officer	Y
Xuan Cung, PharmD	Pharmacy Supervisor (VHP)	Y
Johanna Liu, PharmD, MBA	SCFHP Director of Quality and Pharmacy	Υ
Jeff Robertson, MD	SCFHP Chief Medical Officer	Υ

Non-Voting Committee Members	Specialty	Present (Y or N)
Lily Boris, MD	SCFHP Medical Director	N
Caroline Alexander	SCFHP Administrative Assistant, Medical Management	Υ
Tami Otomo, PharmD	SCFHP Clinical Pharmacist	Υ
Duyen Nguyen, PharmD	SCFHP Clinical Pharmacist	Υ
Dang Huynh, PharmD	SCFHP Pharmacy Manager	Υ
Amy McCarty, PharmD	MedImpact Clinical Program Manager	Υ
Tiffanie Pham, CPhT	SCFHP Pharmacy Coordinator	Υ

	Topic and Discussion	Follow-Up Action
1	Introductions	
	The meeting convened at 6:07 PM.	
2	Public Comment	
	No public comment.	
3	Past Meeting Minutes	
	The SCFHP 1Q2018 P&T Minutes from March 15, 2018 were reviewed by the Committee as submitted.	Upon motion duly made and seconded, the SCFHP 1Q2018 P&T Minutes from March 15, 2018 were approved as



		submitted and will be forwarded to the QI Committee and Board of Directors.
4	Plan Updates	
	Health Plan Updates	
	Dr. Robertson presented the Health Plan Updates. Santa Clara Family	
	Health Plan is moving to the new building on 50 Great Oaks in July.	
	Discussion was had and a vote taken regarding Pharmacy Committee	
	meeting time on a move forward basis in the new building. Proposed	
	start meeting at 6:30 p.m. or continue to meet at 6 pm. Committee	
	voted and it was unanimous to continue meeting at 6 p.m. Health Plan	
	is busy working towards NCQA accreditation. Review period started	
	June 1 st . Site visit will take place in February.	
	Appeals & Grievances	
	Dr. Huynh presented the Appeals & Grievances report Q1 2018. There	
	was a spike in Medi-Cal appeals from December 2017 to January 2018. Q1 2018 58% overturn rate, 23% upheld, 11% partially favorable, 7%	
	withdrawn, and 1% dismissed. For CalMediConnect (CMC), Q12018 Part	
	C&D appeals slight increase from January 2018 to March 2018.	
	Redeterminations Q1 2018, 70% overturned, 27% upheld, 3% partially	
	favorable, 0% dismissed.	
	SCFHP Global DUR	
	Dr. Liu presented and update on Global DUR. Streamlined requirements	
	for managed Medi-Cal plans. Retrospective DUR of opioids.	
	Concomitant use of anticholinergics and antipsychotics. Will present at	
	Pharmacy Committee to share updates.	
	Adjourn to Closed Session	
	Committee adjourned to closed session at 6:30 p.m. to discuss the	
	following items: Membership Report, Pharmacy Dashboard, Drug Use	
	Evaluation Results, Drug Utilization & Spend, Recommendations for	
	Changes to SCFHP Cal MediConnect Formulary and Prior Authorization	
	Criteria, Recommendations for changes to Medi-Cal and Healthy Kids	
	Formulary and Prior Authorization Criteria, DHCS Medi-Cal CDL Updates	
	& Comparability, Prior Authorization Criteria and New Drugs.	
5	Metrics & Financial Updates	
	Membership Report	
	Dr. Robertson presented the membership report.	
	Pharmacy Dashboard	
	Dr. Otomo presented the Pharmacy Dashboard.	
	•	



	Drug Utilization & Spend Review Dr. McCarty presented the Drug Use Evaluation Results.	
	Drug Utilization & Spend Review Dr. McCarty presented the Spend and Trend Overview.	
6	Discussion and Recommendations for changes to SCFHP Cal MediConnect Formulary & Prior Authorization Criteria	
	Dr. Huynh presented an overview of the MedImpact 1Q2018 P&T minutes as well as the MedImpact 2Q2018 P&T Part D Actions.	Upon motion duly made and seconded the MedImpact 1Q2018 P&T Minutes, and MedImpact 2Q2018 P&T Part D Actions were approved as submitted.
7	Discussion and Recommendations for Changes to SCFHP Medi-Cal & Healthy Kids Formulary & Prior Authorization Criteria	
	Formulary Modifications Dr. Otomo presented the formulary changes since the last P&T meeting.	Upon motion duly made and seconded, formulary modifications were approved as presented.
	DHCS Medi-Cal CDL Updates & Comparability Dr. McCarty presented DHCS Medi-Cal CDL Updates & Comparability.	
	Prior Authorization Criteria Dr. Duyen Nguyen presented the following PA criteria for approval by the committee: 1. Diabetic Supplies 2. Androgel 3. Humira 4. Enbrel	Upon motion duly made and seconded, prior authorization criteria were approved as presented.
	New Drugs and Class Reviews Dr. McCarty presented the following new drug reviews: 1. Aimovig 2. Erleada 3. PCSK9 Inhibitors Line Extensions: 1. Noctiva 2. Sinuva 3. Sublocade 4. Lonhala Magnair	Upon motion duly made and seconded, all recommendations were approved as presented.



	5. Firvanq	
	6. Bonjesta	
	7. Zypitamag	
	Reconvene in Open Session	
	Committee reconvened to open session at 7:50 p.m.	
8	Discussion Items	
	Update on New Drugs and Generic Pipeline	
	Dr. McCarty presented the generic pipeline for 1Q2018. High impact	
	drugs: Symdeko, Erleada, Trogarzo, Ilumya, Andexxa, Aimovig,	
	Epidiolex, baricitinib, lorlatinib, Nuvaring, Adcirca, Remodulin, Letairis,	
	Ampyra, Cialis, Tracleer, Kaletra and medium/low impact drugs:	
	Delzicol, Onexton, Zortress, Acanya, Levitra, Androgel, Moviprep,	
	Flector, Proventil HFA, Rapaflo.	
9	Adjournment at 7:55 PM	